Clinical Trial Update: VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating VX15/2503 in combination with avelumab in advanced non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Avelumab (avelumab)
• VX15/2503

Snippet

Sponsor: Vaccinex Inc. | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1, Phase 2 | Status: COMPLETED